Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine

被引:114
作者
Garcia-Hernandez, E.
Gonzalez-Sanchez, J. L.
Andrade-Manzano, A.
Contreras, M. L.
Padilla, S.
Guzman, C. C.
Jimenez, R.
Reyes, L.
Morosoli, G.
Kerde, M. L.
Rosales, R.
机构
[1] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Mol Biol & Biotechnol, Mexico City 04510, DF, Mexico
[2] Inst Mexicano Seguro Social, Hosp Gineco Obstet, Mexico City, DF, Mexico
[3] IMSS, Jefatura Prestaciones, Mexico City, DF, Mexico
[4] Lemery SA CV, Mexico City, DF, Mexico
关键词
papillomavirus; vaccinia virus; MVA; clinical trial; carcinoma in situ;
D O I
10.1038/sj.cgt.7700937
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Human papillomavirus (HPV) is the etiologic agent for cervical cancer. In Mexico, a women dies every 2 h, and since 1990 the statistics have shown that the numbers of deaths are increasing. We conducted a phase II clinical trial to evaluate the potential use of the MVA E2 recombinant vaccinia virus in treating high-grade lesions (CIN 2 and CIN 3) associated with oncogenic papillomavirus. Fifty-four female patients with high degree lesions were treated either with an MVA E2 therapeutic vaccine or with conization. Thirty-four women received the therapeutic vaccine, at a total of 10(7) virus particles per dose injected directly into the uterus once every week over a 6-week period. Twenty control patients were treated with conization. By colposcopy, 19 patients out of 34 showed no lesion, in three patients the lesions were reduced by 85-90%, in eight other lesions had reduced by 60%, and in four more patients, they were reduced by 25%. Histological analysis showed total elimination of high-grade lesions in 20 out of 34 patients after treatment with MVA E2. Eleven patients had a 50% reduction in lesion size. In two other patients, the lesion was reduced to CIN 2 and in one more patient the lesion was reduced to low grade ( CIN 1). All patients developed antibodies against the MVA E2 vaccine, and generated a specific cytotoxic response against papilloma-transformed cells. DNA viral load was significantly reduced in MVA E2-treated patients. Conization eliminated the lesions in 80% of the patients, but patients did not develop cytotoxic activity specific against cancer cells and did not eliminate the papillomavirus. In addition, three patients treated with conization had recurrence of lesions 1 year later. These results show that therapeutic vaccination with MVA E2 proved to be very effective in stimulating the immune system against papillomavirus, and in generating regression of high-grade lesion.
引用
收藏
页码:592 / 597
页数:6
相关论文
共 11 条
  • [1] BINNS MM, 1993, RECOMBINANT POXVIRUS
  • [2] Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
    Gutierrez, CMC
    Tinoco, A
    Navarro, T
    Contreras, ML
    Cortes, RR
    Calzado, P
    Reyes, L
    Posternak, R
    Morosoli, G
    Verde, ML
    Rosales, R
    [J]. HUMAN GENE THERAPY, 2004, 15 (05) : 421 - 431
  • [3] Gutierrez CMC, 2002, HUM GENE THER, V13, P1127
  • [4] Development of a DNA-MVA/HIVA vaccine for Kenya
    Hanke, T
    McMichael, AJ
    Mwau, M
    Wee, EGT
    Ceberej, I
    Patel, S
    Sutton, J
    Tomlinson, M
    Samuel, RV
    [J]. VACCINE, 2002, 20 (15) : 1995 - 1998
  • [5] Human papillomavirus vaccines and prevention of cervical cancer
    Jansen, KU
    Shaw, AR
    [J]. ANNUAL REVIEW OF MEDICINE, 2004, 55 : 319 - 331
  • [6] ESTIMATES OF THE WORLDWIDE FREQUENCY OF 16 MAJOR CANCERS IN 1980
    PARKIN, DM
    LAARA, E
    MUIR, CS
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (02) : 184 - 197
  • [7] MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis
    Roque-Reséndiz, JL
    Rosales, R
    Herion, P
    [J]. PARASITOLOGY, 2004, 128 : 397 - 405
  • [8] A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity
    Rosales, C
    Graham, VV
    Rosas, GA
    Merchant, H
    Rosales, R
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (07) : 347 - 360
  • [9] A RECOMBINANT VECTOR DERIVED FROM THE HOST RANGE-RESTRICTED AND HIGHLY ATTENUATED MVA STRAIN OF VACCINIA VIRUS STIMULATES PROTECTIVE IMMUNITY IN MICE TO INFLUENZA-VIRUS
    SUTTER, G
    WYATT, LS
    FOLEY, PL
    BENNINK, JR
    MOSS, B
    [J]. VACCINE, 1994, 12 (11) : 1032 - 1040
  • [10] Valadez G., 2000, CANCER, V88, P1650